What Does Day One Biopharmaceuticals (DAWN) Do? - Stock Outlook, Earnings, Market Cap, Related Stocks, and Headquarters Guide
An innovative biopharmaceutical company that has conquered the pediatric oncology market with its pediatric low-grade glioma treatment 'Ojemda,' and is now expanding its global footprint after being recently acquired by major global pharmaceutical company Servier.
Subscribe🏢 What does Day One Biopharmaceuticals do?
Day One Biopharmaceuticals is a company founded to deliver precision medicine tailored for pediatric cancer patients. Established in 2018 and headquartered in Brisbane, California, the company has focused on developing innovative drugs designed exclusively for children in the pediatric oncology field, which historically relied on merely administering reduced doses of adult therapies. Thanks to the successful launch of its flagship product Ojemda, the company rapidly emerged as a key player in the global pharmaceutical market within just six years of its founding.
💰 How does it make money?
| Business Segment | Revenue Mix | Description |
|---|---|---|
| Ojemda Product Revenue | ~98% | Sales revenue from the pediatric low-grade glioma treatment, recording triple-digit annual growth rates. |
| Collaboration and Other Revenue | ~2% | License and technology fee revenue from global partners such as Ipsen. |
Ojemda (tovorafenib) is a once-weekly oral therapy with outstanding technological capability to cross the blood-brain barrier. It has established itself as the only systemic treatment option for pediatric brain tumor patients with BRAF fusions or mutations, and within just one year of launch, it surpassed annual revenue of $150 million, demonstrating explosive demand.
📐 Market Cap and Company Scale
The market capitalization stands at $2.2B, which is approximately About 1% of Samsung Electronics' market cap. The company employs 178 people people.
In March 2026, French major pharmaceutical company Servier agreed to acquire Day One for approximately $2.5 billion. This reflects a strong valuation of Day One's leadership in pediatric oncology and its next-generation ADC (antibody-drug conjugate) pipeline. The market cap of $2.2B has been maintained at a level that reflects the acquisition premium following the announcement.
📈 Day One Biopharmaceuticals Outlook and Stock Price Trend
1-Year Price Performance
Analyst Consensus
52-Week Price RangeThe future outlook hinges on the expansion of Ojemda's label into first-line treatment and the clinical progress of next-generation oncology pipeline candidates. As the +20.6% metric shows, robust revenue growth continues, and combined with Servier's global network, expansion into European and Asian markets is expected to accelerate. In addition, next-generation pipeline candidates including the B7-H4-targeted ADC licensed from Mersana are anticipated to deliver substantial clinical data starting in the second half of 2026.
⚔️ Core Competitive Strengths and Risks
Day One Bio has secured a unique position in the pediatric oncology market and the backing of a major pharmaceutical company, but the concentration of revenue on a single product and the success of its new ADC pipeline remain factors to monitor.
💪 Core Competitive Strengths
⚠️ Core Risks
Competitors and Related Stocks (Beneficiaries)
The most direct competitors in the pediatric oncology treatment market include Novartis (NVS) and AstraZeneca (AZN). In the next-generation ADC space, the activities of GSK and Eli Lilly (LLY) also warrant attention, and the company is frequently compared with BioMarin (BMRN) in the pediatric rare disease space within the investment community.
✅ Investor Checkpoints
To assess the future value of Day One Bio, please monitor the following three key milestones.
| Checkpoint | What to Verify | Current Status |
|---|---|---|
| ✅ Servier Acquisition Completion | Finalization of the acquisition process scheduled for Q2 2026 and any potential delisting | In Progress |
| ✅ Ojemda First-Line Treatment Approval | Label expansion outcomes based on results from the ongoing Phase 3 clinical trial (FIREFLY-2) | Positive |
| ✅ ADC Clinical Data Release | Initial safety and efficacy data from new ADC pipeline candidates including Emi-Le | In Progress |
Investors should note that until the M&A transaction is completed, stock price volatility may arise due to potential delays in deal closing or changes in deal terms.
In conclusion, Day One Bio has written a unique success story in the specialized field of pediatric oncology. As the company aims for greater growth within the embrace of a major pharmaceutical company, its value as an innovative pharmaceutical stock appears highly compelling.
Check Day One Biopharmaceuticals' real-time quotes, technical indicators, and peer comparisons at a glance on US Stock Today's real-time dashboard.
Subscribe Today's 5 AI picks, all free